COVID-19 in Nigeria, West Africa: An Update

Author(s): Adekunle Odunayo Adejuwon, Olubunmi Sharon Obayemi, Olaleke David Odeleye, Victoria Anatolyivna Tsygankova

Full Text: PDF

Published: 2020-06-12


Background: Recently, SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) identified and classified as a single stranded (positive sense) RNA virus causes COVID-19 (Coronavirus disease 2019). It was first detected in China. Symptoms of the disease include severe acute respiratory syndrome. The disease has become pandemic affecting the globe. No vaccine has been discovered to be of impact in the control of this deadly disease. MERS-CoV (Middle East Respiratory Syndrome Coronavirus) recognizes DPP4 (dipeptidyl peptidase 4) as its receptor. ACE2 (Angiotensin-Converting Enzyme 2) is a receptor for SARS-CoV. COVID-19 is zoonotic, probably of feline origin or from bats. In the United States, hydroxychloroquine sulphate and zinc in combination with the antibiotic azithromycin or doxycyline is currently under clinical trial and being investigated as a possible potential therapy for COVID-19. Investigation: Presently, in Nigeria, West Africa, infection with SARS-CoV-2 is being managed with seemingly minimal mortality. In this investigation, the alcohol extract of a combination of Garcinia kola seeds and Zingiber officinale leaves, with medicinal value, used locally in some western parts of Nigeria, is being explored as a potential therapeutic application for COVID-19.


Copyright © 2020 Infinity Press. All rights reserved.